The Effectiveness of Early Immunisation With Nirsevimab on Preschool Wheezing in France, Based on an Analysis of Data From the French Health System Database.
This study is investigating whether a preventative injection called nirsevimab can reduce wheezing issues in young children. Wheezing, especially repeated episodes in early childhood, can sometimes be a sign of future breathing problems like asthma. Researchers in France are looking at health records to see if babies who received nirsevimab in their first six months of life had fewer hospital stays for wheezing when they were toddlers (between one and two years old). They want to understand if protecting babies early from a common virus called RSV, which nirsevimab helps against, can have a lasting positive effect on their breathing health as they grow. This type of study uses information already collected by the health system, so no new tests or procedures are involved for the children and families.
At a glance
What is this study about?
This study is all about trying to understand if giving babies an injection called nirsevimab early in their lives can help prevent them from developing wheezing problems as they grow into toddlers and preschoolers. Many young children get a common illness called RSV (Respiratory Syncytial Virus), which often causes them to have breathing difficulties and wheezing. Sometimes, having RSV infections early in life can lead to more wheezing later, and even increase the chance of developing asthma.
Nirsevimab is a special antibody that acts like a shield, helping to protect babies from severe RSV infections. We already know it's very good at stopping babies from needing to go to hospital with RSV. But doctors want to know if preventing these severe early infections can also stop recurrent wheezing from happening in the first place, or at least make it less severe. This study aims to answer that important question – can early protection from RSV improve children's breathing health over the long term?
To do this, researchers in France are carefully looking at existing health records. They are comparing how often babies who received nirsevimab ended up in hospital for wheezing during their second year of life, compared to babies who didn't receive the injection. This kind of study, which uses information already collected by the health system, helps us learn more about real-world effects of treatments without having to ask people to sign up for new studies or go through extra medical appointments.
Key takeaways
- This study is looking at whether an RSV protective injection (nirsevimab) helps reduce wheezing in young children.
- It uses existing health records from France, not new tests or appointments.
- The aim is to see if early protection from RSV can prevent future breathing problems like wheezing.
- Researchers are comparing babies who received nirsevimab with those who didn't.
- The results could help doctors understand how to better prevent childhood wheezing and potentially asthma.
Who may be eligible?
This study is looking at medical records of babies born in France between February 2023 and January 2024. The 'exposed' group includes babies who received the nirsevimab injection before they were 6 months or 12 months old, depending on specifically what the researchers are looking at. The 'unexposed' group includes babies born during the same time who did not receive nirsevimab.
Some babies' records are not included. For example, if a baby was born in certain overseas French territories, or if they are identical twins (because medical records might not be able to tell them apart easily). Also, if a mother received an RSV vaccine during pregnancy, or if a baby received a different type of protection called palivizumab, their records won't be part of this study.
Finally, if a baby had already been hospitalised for wheezing or an RSV infection before they received nirsevimab, their records won't be used. This helps the researchers make sure they are looking at the effects of nirsevimab on preventing wheezing, not treating existing problems.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Was your child born in France between February 2023 and January 2024?
- Did your child receive the nirsevimab injection (or not, if in the comparison group)?
- Was your child *not* born in an overseas French territory?
- Did your child *not* have another RSV protective injection (palivizumab)?
- Did your child *not* have a severe RSV infection or wheezing requiring hospitalisation *before* receiving nirsevimab?
What does participation involve?
This study does not involve direct participation from you or your child. Researchers are using information that has already been collected as part of routine healthcare in France. This means you won't need to attend any appointments, answer any questionnaires, or take any medication. Your child's medical records are being reviewed anonymously and securely to understand the effects of nirsevimab. There are no visits, assessments, or follow-up actions required from you or your child for this study.
Potential risks and benefits
Locations (1)
- Hospices Civils de Lyon - Hôpital Femme Mère EnfantVerified postcodeBron, France
Common questions
What is nirsevimab?
Nirsevimab is a special injection given to babies to help protect them from severe infections caused by a common virus called RSV (Respiratory Syncytial Virus).
What is RSV?
RSV is a common virus that can affect anyone, but it can cause serious breathing problems, like bronchiolitis, in very young babies.
What is 'preschool wheezing'?
This refers to repeated episodes of wheezing (a whistling sound during breathing) that young children experience before they start primary school, usually between ages 2 and 6.
Will my child's information be safe?
Yes, researchers are using anonymised health records, which means your child's personal details are not directly linked to the data they are studying.
Do I need to do anything for this study?
No, you don't need to do anything. This study is analysing existing health data from France, so there's no direct participation required from families.
How to find out more
REIX P REIX, P, Pr, Pr
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.